<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26729152</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Development of Novel Vaccines against Enterovirus-71.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v8010001</ELocationID><Abstract><AbstractText>The hand, foot and mouth disease is caused by a group of Enteroviruses such as Enterovirus 71 (EV-A71) and Coxsackievirus CV-A5, CV-A8, and CV-A16. Mild symptoms of EV-A71 infection in children range from high fever, vomiting, rashes and ulcers in mouth but can produce more severe symptoms such as brainstem and cerebellar encephalitis, leading up to cardiopulmonary failure and death. The lack of vaccines and antiviral drugs against EV-A71 highlights the urgency of developing preventive and treatment agents against EV-A71 to prevent further fatalities. Research groups have developed experimental inactivated vaccines, recombinant Viral Protein 1 (VP1) vaccine and virus-like particles (VLPs). The inactivated EV-A71 vaccine is considered the safest viral vaccine, as there will be no reversion to the infectious wild type strain. The recombinant VP1 vaccine is a cost-effective immunogen, while VLPs contain an arrangement of epitopes that can elicit neutralizing antibodies against the virus. As each type of vaccine has its advantages and disadvantages, increased studies are required in the development of such vaccines, whereby high efficacy, long-lasting immunity, minimal risk to those vaccinated, safe and easy production, low cost, dispensing the need for refrigeration and convenient delivery are the major goals in their design.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yee</LastName><ForeName>Pinn Tsin Isabel</ForeName><Initials>PT</Initials><AffiliationInfo><Affiliation>Virology Research Group, Vice Chancellor's Office, Sunway University, Bandar Sunway, Kuala Lumpur, Selangor 47500, Malaysia. isabely@sunway.edu.my.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poh</LastName><ForeName>Chit Laa</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Virology Research Group, Vice Chancellor's Office, Sunway University, Bandar Sunway, Kuala Lumpur, Selangor 47500, Malaysia. pohcl@sunway.edu.my.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>12</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="N">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Enterovirus 71</Keyword><Keyword MajorTopicYN="N">foot and mouth disease</Keyword><Keyword MajorTopicYN="N">hand</Keyword><Keyword MajorTopicYN="N">inactivated vaccine</Keyword><Keyword MajorTopicYN="N">viral like particles</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26729152</ArticleId><ArticleId IdType="pmc">PMC4728561</ArticleId><ArticleId IdType="doi">10.3390/v8010001</ArticleId><ArticleId IdType="pii">v8010001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Small J.C., Ertl H.C. Viruses&#x2014;From pathogens to vaccine carriers. Curr. Opin. Virol. 2011;1:241&#x2013;245. doi: 10.1016/j.coviro.2011.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2011.07.009</ArticleId><ArticleId IdType="pmc">PMC3190199</ArticleId><ArticleId IdType="pubmed">22003377</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing W., Liao Q., Viboud C., Zhang J., Sun J., Wu J.T., Chang Z., Liu F., Fang V.J., Zheng Y., et al. Hand, foot, and mouth disease in China, 2008&#x2013;12: An epidemiological study. Lancet Infect. Dis. 2014;14:308&#x2013;318. doi: 10.1016/S1473-3099(13)70342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(13)70342-6</ArticleId><ArticleId IdType="pmc">PMC4035015</ArticleId><ArticleId IdType="pubmed">24485991</ArticleId></ArticleIdList></Reference><Reference><Citation>Bible J.M., Pantelidis P., Chan P.K.S., Tong C.Y.W. Genetic evolution of enterovirus 71: Epidemiological and pathological implications. Rev. Med. Virol. 2007;17:371&#x2013;379. doi: 10.1002/rmv.538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.538</ArticleId><ArticleId IdType="pubmed">17487831</ArticleId></ArticleIdList></Reference><Reference><Citation>Pallansch M.A., Oberste M.S., Whitton J.L. Enteroviruses: Polioviruses, coxsackieviruses, echoviruses and newer enteroviruses. In: Knipe D.M., Howley P.M., Cohen J.I., Griffin D.E., Lamb R.A., Martin M.A., Racaniello V.R., Roizman B., editors. Fields Virology. 6th ed. Lippincott Williams &amp; Wilkins; Philadelphia, PA, USA: 2003. pp. 490&#x2013;530.</Citation></Reference><Reference><Citation>Liu S.L., Pan H., Liu P., Amer S., Chan T.C., Zhan J., Huo X., Liu Y., Teng Z., Wang L., Zhuang H. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014. Rev. Med. Virol. 2015;25:115&#x2013;28. doi: 10.1002/rmv.1827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.1827</ArticleId><ArticleId IdType="pubmed">25704797</ArticleId></ArticleIdList></Reference><Reference><Citation>Melnick J.L. Poliovirus and other enteroviruses. In: Evans A.S., Kaslow R.A., editors. Viral Infections of Humans. Plenum; New York, NY, USA: 1997. pp. 583&#x2013;663.</Citation></Reference><Reference><Citation>Ooi M.H., Wong S.C., Lewthwaite P., Cardosa M.J., Solomon T. Clinical features, diagnosis, and management of enterovirus 71. Lancet Neurol. 2010;9:1097&#x2013;1105. doi: 10.1016/S1474-4422(10)70209-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70209-X</ArticleId><ArticleId IdType="pubmed">20965438</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.R., Hsu K.H., Twu S.J., Chen K.T., Tsai S.F., Wang J.R., Shih S.R. An epidemic of enterovirus 71 infection in Taiwan. N. Engl. J. Med. 1999;341:929&#x2013;935. doi: 10.1056/NEJM199909233411301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu M., Su L., Cao L., Zhong H., Dong N., Xu J. Enterovirus genotypes causing hand foot and mouth disease in Shanghai, China: A molecular epidemiological analysis. BMC Infect. Dis. 2013;13:489&#x2013;497. doi: 10.1186/1471-2334-13-489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2334-13-489</ArticleId><ArticleId IdType="pmc">PMC4015791</ArticleId><ArticleId IdType="pubmed">24148902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown B.A., Pallansch M.A. Complete nucleotide sequence of Enterovirus 71 is distinct from poliovirus. Virus Res. 1995;39:195&#x2013;205. doi: 10.1016/0168-1702(95)00087-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-1702(95)00087-9</ArticleId><ArticleId IdType="pubmed">8837884</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee K.K., Lam T.T., Chan Y.F., Bible J.M., Kamarulzaman A., Tong C.Y., Takebe Y., Pybus O.G. Evolutionary genetics of human enterovirus 71: Origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 2010;84:3339&#x2013;3350. doi: 10.1128/JVI.01019-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01019-09</ArticleId><ArticleId IdType="pmc">PMC2838098</ArticleId><ArticleId IdType="pubmed">20089660</ArticleId></ArticleIdList></Reference><Reference><Citation>Picornaviridae.  [(accessed on 12 October 2014)].  Available online:  http://viralzone.expasy.org/all_by_species/33.html.</Citation></Reference><Reference><Citation>Belsham G.J., Sonenberg N. RNA-protein interactions in regulation of picornavirus RNA translation. Microbiol. Rev. 1996;60:499&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC239454</ArticleId><ArticleId IdType="pubmed">8840784</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda H., Nicklin M.J.H., Murray M.G., Anderson C.W., Dunn J.J., Studier F.W., Wimmer E. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell. 1986;45:761&#x2013;770. doi: 10.1016/0092-8674(86)90790-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(86)90790-7</ArticleId><ArticleId IdType="pubmed">3011278</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen M., Reitman Z.J., Zhao Y., Moustafa I., Wang Q., Arnold J.J., Pathak H.B., Cameron C.E. Picornavirus genome replication: Identification of the surface of the poliovirus (PV) 3C dimer that interacts with PV 3Dpol during VPg uridylylation and construction of a structural model for the PV 3C2&#x2013;3Dpol complex. J. Biol. Chem. 2008;283:875&#x2013;888. doi: 10.1074/jbc.M707907200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M707907200</ArticleId><ArticleId IdType="pmc">PMC2186065</ArticleId><ArticleId IdType="pubmed">17993457</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo R.L., Kung S.H., Hsu Y.Y., Liu W.T. Infection with enterovirus 71 or expression of its 2A protease induces apoptotic cell death. J. Gen. Virol. 2002;83:1367&#x2013;1376. doi: 10.1099/0022-1317-83-6-1367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-83-6-1367</ArticleId><ArticleId IdType="pubmed">12029152</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M.L., Hsu T.A., Chen T.C., Chang S.C., Lee J.C., Chen C.C., Stollar V., Shih S.R. The 3C protease activity of Enterovirus 71 induces human neural cell apoptosis. Virology. 2002;293:386&#x2013;395. doi: 10.1006/viro.2001.1310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2001.1310</ArticleId><ArticleId IdType="pubmed">11886259</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt N., Lennette E., Ho H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J. Infect. Dis. 1974;129:304&#x2013;309. doi: 10.1093/infdis/129.3.304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>The Dermatologic Image Database, Department of Dermatology, University of Iowa College of Medicine, USA. 1996.  [(accessed on 1 September 2015)].  Available online:  http://tray.dermatology.uiowa.edu/ImageBase.</Citation></Reference><Reference><Citation>Lin T.Y., Chang L.Y., Hsia S.H., Huang Y.C., Chiu C.H., Hsueh C., Shih S.R., Liu C.C., Wu M.H. The 1998 Enterovirus 71 outbreak in Taiwan: Pathogenesis and management. Clin. Infect. Dis. 2002;34:S52&#x2013;S57. doi: 10.1086/338819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/338819</ArticleId><ArticleId IdType="pubmed">11938497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabanathan S., Tan L.V., Thwaites L., Wills B., Qui P.T., van Doorn H.R. Enterovirus 71 related severe hand, foot and mouth disease outbreaks in South-East Asia: Current situation and ongoing challenges. J. Epidemiol. Commun. Health. 2014;0:1&#x2013;3. doi: 10.1136/jech-2014-203836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jech-2014-203836</ArticleId><ArticleId IdType="pmc">PMC4033151</ArticleId><ArticleId IdType="pubmed">24652348</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Emerging Disease Surveillance and Response: Hand, Foot and Mouth Disease (HFMD)  [(accessed on 22 February 2015)].  Available online:  http://www.wpro.who.int/emerging_diseases/HFMD/en/</Citation></Reference><Reference><Citation>Xu W., Liu C.F., Yan L., Li J. J., Wang L.J., Qi Y., Cheng R.B., Xiong X.Y. Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications. Virol. J. 2012;9:8&#x2013;16. doi: 10.1186/1743-422X-9-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-9-8</ArticleId><ArticleId IdType="pmc">PMC3268717</ArticleId><ArticleId IdType="pubmed">22230340</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z.L., Mao Q.Y., Wang Y.P., Zhu F.C., Li J.X., Yao X., Gao F., Wu X., Xu M., Wang J.Z. Progress on the research and development of inactivated EV71 whole-virus vaccines. Hum. Vaccines Immunother. 2013;9:1701&#x2013;1705. doi: 10.4161/hv.24949.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.24949</ArticleId><ArticleId IdType="pmc">PMC3906269</ArticleId><ArticleId IdType="pubmed">23744508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.N., Lin Y.C., Fann C., Liao N.S., Shih S.R., Ho M.S. Protection against lethal Enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine. 2001;20:895&#x2013;904. doi: 10.1016/S0264-410X(01)00385-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Shimizu H., Nagata N., Ami Y., Suzaki Y., Sata T., Iwasaki T., Miyamura T. Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys. J. Gen. Virol. 2005;86:1391&#x2013;1401. doi: 10.1099/vir.0.80784-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/vir.0.80784-0</ArticleId><ArticleId IdType="pubmed">15831951</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Nagata N., Iwata N., Ami Y., Suzaki Y., Mizuta K., Iwasaki T., Sata T., Wakita T., Shimizu H. An attenuated strain of enterovirus 71 belonging to genotype A showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J. Virol. 2007;81:9386&#x2013;9395. doi: 10.1128/JVI.02856-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02856-06</ArticleId><ArticleId IdType="pmc">PMC1951441</ArticleId><ArticleId IdType="pubmed">17567701</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H.Y., Han J.F., Qin C.F., Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine. 2013;31:3281&#x2013;3287. doi: 10.1016/j.vaccine.2013.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Foo D.G.W., Alonso S., Chow V.T.K., Poh C.L. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect. 2007;9:1299&#x2013;1306. doi: 10.1016/j.micinf.2007.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2007.06.002</ArticleId><ArticleId IdType="pubmed">17890123</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk K., Poh C.L., Fecondo J., Pourianfar H., Shaw J., Grollo L. Cross-reactive neutralizing antibody epitopes against enterovirus 71 identified by an in silico approach. Vaccine. 2012;30:7105&#x2013;7110. doi: 10.1016/j.vaccine.2012.09.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.09.030</ArticleId><ArticleId IdType="pubmed">23022400</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W., Bakar S., Sekawi Z., Rosli R. DNA vaccine constructs against Enterovirus 71 elicit immune response in mice. Genet. Vaccines Ther. 2007;5:1&#x2013;13. doi: 10.1186/1479-0556-5-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-0556-5-6</ArticleId><ArticleId IdType="pmc">PMC3225814</ArticleId><ArticleId IdType="pubmed">17445254</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., Liang Z., Liu Y., Zhang X., Tan X., Wang L., Mao Q., Wu J., et al. Efficacy, safety, and immunogenicity of an Enterovirus 71 vaccine in China. N. Engl. J. Med. 2014;370:818&#x2013;828. doi: 10.1056/NEJMoa1304923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F.C., Meng F.Y., Li J.X., Li X.L., Mao Q.Y., Tao H., Zhang Y.T., Yao X., Chu K., Chen Q.H., et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant Enterovirus 71 vaccine in children in china: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2013;381:2024&#x2013;2032. doi: 10.1016/S0140-6736(13)61049-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Liu C.C., Chow Y.H., Chou A.H., Klein M. Review of Enterovirus 71 vaccines. Clin. Infect. Dis. 2015;60:797&#x2013;803. doi: 10.1093/cid/ciu852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciu852</ArticleId><ArticleId IdType="pubmed">25352588</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.F., Chang M.H., Chiang B.L., Jeng S.T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from Enterovirus 71. Vaccine. 2006;24:2944&#x2013;2951. doi: 10.1016/j.vaccine.2005.12.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2005.12.047</ArticleId><ArticleId IdType="pubmed">16448730</ArticleId></ArticleIdList></Reference><Reference><Citation>Han J.F., Cao R.Y., Deng Y.Q., Tian X., Jiang T., Qin E.D., Qin C.F. Antibody dependent enhancement infection of Enterovirus 71 in vitro and in vivo. Virol. J. 2011;8:106. doi: 10.1186/1743-422X-8-106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-8-106</ArticleId><ArticleId IdType="pmc">PMC3060144</ArticleId><ArticleId IdType="pubmed">21385398</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer P., Charley B., Rombaut B., Daeron M., Lebon P. Antibody-dependent induction of type I interferons by poliovirus in human mononuclear blood cells requires the type II Fc&#x3b3; receptor (CD32) Virology. 2000;278:86&#x2013;94. doi: 10.1006/viro.2000.0627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/viro.2000.0627</ArticleId><ArticleId IdType="pubmed">11112484</ArticleId></ArticleIdList></Reference><Reference><Citation>Girn J., Kavoosi M., Chantler J. Enhancement of coxsackievirus B3 infection by antibody to a different coxsackievirus strain. J. Gen. Virol. 2002;83:351&#x2013;358. doi: 10.1099/0022-1317-83-2-351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-83-2-351</ArticleId><ArticleId IdType="pubmed">11807228</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z., Wang J. EV71 vaccine, an invaluable gift for children. Clin. Trans. Immunol. 2014;3:e28. doi: 10.1038/cti.2014.24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2014.24</ArticleId><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Mo Z., Liang Z., Zhang Y., Li R., Ong K.C., Wong K.T., Yang E., Che Y., Wang J., et al. Immunity and clinical efficacy of an inactivated Enterovirus 71 vaccine in healthy Chinese children: A report of further observations. BMC Med. 2015;13:226. doi: 10.1186/s12916-015-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0448-7</ArticleId><ArticleId IdType="pmc">PMC4574357</ArticleId><ArticleId IdType="pubmed">26381232</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q., Dong C., Li X., Gao Q., Guo Z., Yao X., Wang Y., Gao F., Li F., Xu M., et al. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS ONE. 2012;7:1. doi: 10.1371/journal.pone.0046043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046043</ArticleId><ArticleId IdType="pmc">PMC3460965</ArticleId><ArticleId IdType="pubmed">23029378</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong P., Hsieh S.Y., Liu C.C., Chou A.H., Chang J.Y., Wu S.C., Liu S.J., Chow Y.H., Su I.J., Klein M. Production of EV71 vaccine candidates. Hum. Vaccines Immunother. 2012;8:1775&#x2013;1783. doi: 10.4161/hv.21739.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.21739</ArticleId><ArticleId IdType="pmc">PMC3656065</ArticleId><ArticleId IdType="pubmed">22992566</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek E.J., Hussain K.M., Phuektes P., Kok C.C., Gao Q., Cai F., Gao Z., McMinn P.C. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine. 2011;29:4829&#x2013;4838. doi: 10.1016/j.vaccine.2011.04.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.070</ArticleId><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., An D., Liu W., Mao Q., Jin J., Xu L., Sun S., Jiang L., Li X., Shao J., et al. Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay. PLoS ONE. 2014;9:1. doi: 10.1371/journal.pone.0100545.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100545</ArticleId><ArticleId IdType="pmc">PMC4070950</ArticleId><ArticleId IdType="pubmed">24964084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S. EV71 vaccines: A milestone in the history of global vaccine development. Emerg. Microbes Infect. 2014;3:e27. doi: 10.1038/emi.2014.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emi.2014.29</ArticleId><ArticleId IdType="pmc">PMC4008769</ArticleId><ArticleId IdType="pubmed">26038519</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereghino J.L., Cregg J.M. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. Rev. 2000;24:45&#x2013;66. doi: 10.1111/j.1574-6976.2000.tb00532.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2000.tb00532.x</ArticleId><ArticleId IdType="pubmed">10640598</ArticleId></ArticleIdList></Reference><Reference><Citation>Rold&#xe3;o A., Mellado M.C., Castilho L.R., Carrondo M.J.T., Alves P.M. Virus-like particles in vaccine development. Expert Rev. Vaccines. 2010;9:1149&#x2013;1176. doi: 10.1586/erv.10.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/erv.10.115</ArticleId><ArticleId IdType="pubmed">20923267</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Ku Z., Liu Q., Wang X., Chen T., Ye X., Li D., Jin X., Huang Z. High-yield production of recombinant virus-like particles of Enterovirus 71 in Pichia pastoris and their protective efficacy against oral viral challenge in mice. Vaccine. 2015;33:2335&#x2013;2341. doi: 10.1016/j.vaccine.2015.03.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2015.03.034</ArticleId><ArticleId IdType="pubmed">25820068</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou A.H., Liu C.C., Chang J.Y., Lien S.P., Guo M.S., Tasi H.P., Hsiao K.N., Liu S.J., Sia C., Wu S.C., et al. Immunological evaluation and comparison of different EV71 vaccine candidates. Clin. Dev. Immunol. 2012;2012:831282. doi: 10.1155/2012/831282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/831282</ArticleId><ArticleId IdType="pmc">PMC3447357</ArticleId><ArticleId IdType="pubmed">23008736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S.Y., Yeh C.T., Li W.H., Yu C.P., Lin W.C., Yang J.Y., Wu H.L., Hu Y.C. Enhanced enterovirus 71 virus-like particle yield from a new baculovirus design. Biotechnol. Bioeng. 2015;112:2005&#x2013;2015. doi: 10.1002/bit.25625.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bit.25625</ArticleId><ArticleId IdType="pmc">PMC7161748</ArticleId><ArticleId IdType="pubmed">25997678</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsou Y.L., Lin Y.W., Shao H.Y., Yu S.L., Wu S.R., Lin H.Y., Liu C.C., Huang C., Chong P., Chow Y.H. Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS Negl. Trop. Dis. 2015;9:1. doi: 10.1371/journal.pntd.0003692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pntd.0003692</ArticleId><ArticleId IdType="pmc">PMC4391779</ArticleId><ArticleId IdType="pubmed">25855976</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Li H.Y., Han J.F., Deng Y.Q., Zhu S.Y., Li X.F., Yang H.Q., Li Y.X., Zhang Y., Qin E.D. Novel recombinant chimeric virus-like particle is immunogenic and protective against both Enterovirus 71 and Coxsackievirus A16 in mice. Sci. Rep. 2015;5:7878&#x2013;7886. doi: 10.1038/srep07878.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep07878</ArticleId><ArticleId IdType="pmc">PMC4297979</ArticleId><ArticleId IdType="pubmed">25597595</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., He D., Yang L., Li Z., Ye X., Yu H., Zhao H., Li S., Yuan L., Qian H., et al. A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of Enterovirus 71. Sci. Rep. 2015;5:12973&#x2013;12985. doi: 10.1038/srep12973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep12973</ArticleId><ArticleId IdType="pmc">PMC4525384</ArticleId><ArticleId IdType="pubmed">26243660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., Wang G.C., He Y.L., Han J.F., Ye Q., Qin C.F., Chen R. Crystal structures of EV71 recombinant virus particles provide insights into vaccine design. J. Biol. Chem. 2014;290:3198&#x2013;3208. doi: 10.1074/jbc.M114.624536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M114.624536</ArticleId><ArticleId IdType="pmc">PMC4318995</ArticleId><ArticleId IdType="pubmed">25492868</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu K., He Y.L., Li H.Y., Chen R. Crystal structures of yeast-produced enterovirus 71 and enterovirus 71/coxsackievirus A16 chimeric virus-like particles provide the structural basis for novel vaccine design against hand-foot-and-mouth disease. J. Virol. 2015;89:6196&#x2013;6208. doi: 10.1128/JVI.00422-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00422-15</ArticleId><ArticleId IdType="pmc">PMC4474312</ArticleId><ArticleId IdType="pubmed">25833050</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G., Cao R.Y., Chen R., Mo L., Han J.F., Wang X., Xu X., Jiang T., Deng Y.Q., Lyu K., et al. Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions. Proc. Natl. Acad. Sci. USA. 2013;110:7619&#x2013;7624. doi: 10.1073/pnas.1300233110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1300233110</ArticleId><ArticleId IdType="pmc">PMC3651461</ArticleId><ArticleId IdType="pubmed">23589862</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Cardosa J., Kuhn R., Rossman M.G. Crystal structure of human Enterovirus 71. Science. 2012;336:1274&#x2013;1276. doi: 10.1126/science.1218713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1218713</ArticleId><ArticleId IdType="pmc">PMC3448362</ArticleId><ArticleId IdType="pubmed">22383808</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X., Peng W., Ren J., Hu Z., Xu J., Lou Z., Li X., Yin W., Shen X., Porta C., et al. A sensor-adaptor mechanism for enterovirus uncoating from structures of EV71. Nat. Struct. Mol. Biol. 2012;19:424&#x2013;429. doi: 10.1038/nsmb.2255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb.2255</ArticleId><ArticleId IdType="pmc">PMC3378640</ArticleId><ArticleId IdType="pubmed">22388738</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolla-Pazner S., Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat. Rev. Immunol. 2010;10:527&#x2013;535. doi: 10.1038/nri2801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2801</ArticleId><ArticleId IdType="pmc">PMC3167078</ArticleId><ArticleId IdType="pubmed">20577269</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>